Debbie Rigby rounds up the latest in research news
SGLT-2 inhibitors have a positive effect on the progression of chronic kidney disease. A systematic review and meta-analysis of the effect of SGLT-2 inhibitors on renal adverse events shows they also reduce the odds of suffering acute kidney injury by 36%.
PLoS Med 16(12): e1002983.
A real-world cohort study conducted in Taiwan shows that NOACs (dabigatran, rivaroxaban, and apixaban) reduce fracture risk compared to warfarin. NOACs reduced hip, vertebral, or humerus/forearm/wrist fractures risks by 16%. Atrial fibrillation is an independent risk factor for osteoporotic fractures.
European Heart Journal, ehz952.
This article discusses opioid use disorder, opioid receptor physiology, and opioid withdrawal symptomatology and pathophysiology, as well as current treatment options available to reduce opioid withdrawal symptoms in individuals with physical dependence and/or opioid use disorder.
Journal of Clinical Pharmacy and Therapeutics 2020;00:1–12.
This study suggests that within the Australian general practice setting, osteoporosis is underdiagnosed and undertreated. In addition, it appears that most patients who ceased denosumab treatment had no record of subsequent antiresorptive therapy, which would place them at risk of further fractures. The study supports the need for the development of clinical education programs addressing GP knowledge gaps and attitudes, and the implementation of specific interventions such as good reminder/recall systems to avoid delays in reviewing and treating patients with osteoporosis.
BMC Fam Pract 2020;21:32.